Beond
Beond operates a medically supervised ibogaine treatment program in a hospital-grade Cancún, Mexico facility, serving self-pay individuals with treatment-resistant depression, trauma, PTSD, addiction, and veteran-related conditions through a proprietary 5-phase neurorestorative protocol, with U.S. expansion underway.
- Company typePrivate
- Founded2021
- HeadquartersSan Francisco, Mexico
- Headcount11–50
- GTM typeB2C
- OfferingServices
What Beond does
Beond operates a medically supervised ibogaine treatment program delivered inside a hospital-grade clinical facility in Cancún, Quintana Roo, Mexico. Its core offering is a proprietary 5-Phase Neurorestorative Program that spans remote therapeutic preparation, onsite pre-treatment medical assessment by licensed physicians and ICU-certified nurses, ibogaine administration with advanced cardiac monitoring, acute aftercare, and long-term coaching. Distinct programs address mood/trauma/PTSD, chemical dependency and behavioral addiction (opioids, Fentanyl, stimulants, alcohol), personal growth and peak performance, and a dedicated Beond Service line for veterans and first responders; a private-retreat tier is offered under the Beondblack sub-brand, with adjacent Beondthebeach and Beondresearch units.
The company serves self-pay individual consumers seeking treatment for conditions that have not responded to conventional care. Patient acquisition runs almost entirely through direct-to-consumer channels: website-driven consultation booking, organic social on Instagram, YouTube, TikTok, and Facebook, a company podcast, and high-leverage earned media. Notable placements include the Joe Rogan Experience, testimonials from Jordan Belfort and Dr. Mark Hyman, MD, and coverage in Forbes, the Washington Post, the New York Post, PBS, the Houston Chronicle, Fox News, and the Associated Press. Revenue is generated on a quote-based fee-for-service basis; pricing is not publicly disclosed, and over 3,000 patients have been treated cumulatively since founding in 2021 by Talia Eisenberg, with CEO Tom Feegel leading public positioning.
Strategically, Beond has announced expansion into Austin, Texas to provide U.S.-based education, preparation, and aftercare, signaling a future domestic clinical presence. The company is actively aligning with the federal psychedelic policy shift, including President Trump's executive order accelerating FDA psychedelic reviews and reported $50M HHS and $100M Texas-level commitments to ibogaine research, and has stated intent to contribute clinical data toward U.S. regulatory standards. Initial institutional capital came from Empath Ventures in October 2021; the company remains privately held with 11–50 employees and no disclosed parent, M&A, or subsequent funding rounds.
Beond firmographics
Firmographics- Name
- Beond
- Legal name
- Beond Ibogaine
- Website
- https://beond.us
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Beond operates a medically supervised ibogaine treatment program in a hospital-grade Cancún, Mexico facility, serving self-pay individuals with treatment-resistant depression, trauma, PTSD, addiction, and veteran-related conditions through a proprietary 5-phase neurorestorative protocol, with U.S. expansion underway.
- Ownership category
- akta.pro rank
Beond industry classification
Industry- Product category
- Psychedelic-Assisted Therapy
- NAICS
- Residential Mental Health and Substance Abuse Facilities (623220), Other Ambulatory Health Care Services (6219)
- SIC
- Services-Nursing & Personal Care Facilities (8050)
- akta.pro primary industry
- Residential Substance Use Rehabilitation (Inpatient Rehab) (HLAFACAE)
- akta.pro secondary industries
- Outpatient Substance Use Treatment Programs (IOP/PHP/OP) (HLAFACAF), Outpatient Substance Use Disorder (SUD) Treatment Programs (HLAFABAD)
Keywords
Where Beond is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- Mexico
- HQ region
- Latin America
Offices2 records
Markets served
Beond business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Ibogaine Treatment Services: Fee-for-service treatment program where patients pay for the 5-phase neurorestorative program including preparation, onsite treatment, and aftercare support. Pricing appears to be quote-based and not publicly disclosed on website.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Beond product offering
Product offeringCore offering
Beond provides medically supervised ibogaine-assisted treatment delivered in a hospital-grade clinical environment in Cancún, Mexico, treating depression, anxiety, PTSD, traumatic brain injury, trauma, and substance addictions (opioids, fentanyl, stimulants, alcohol). Treatment is structured around a proprietary 5-phase neurorestorative program that spans remote preparation, on-site medical assessment, ibogaine administration with advanced cardiac monitoring, acute integration, and long-term aftercare coaching.
Product overview
Beond is a neuroplasticity medicine company offering a unified treatment platform centered on medically supervised ibogaine therapy delivered in hospital-grade clinical facilities. The core offering is the 5-Phase Neurorestorative Program, which combines remote preparation, onsite pre-treatment, ibogaine-based neuroplasticity treatment with advanced cardiac monitoring, acute aftercare, and long-term aftercare coaching. Treatment programs address Mood/Trauma/PTSD, Chemical Dependency/Behavioral Addiction, and Personal Growth/Peak Performance, with specialized Beond Service offerings for Veterans and First Responders. The company also operates Private Retreats as a sub-brand through beondblack.com, and provides Therapeutic Coaching as an integrated add-on service.
Differentiator
Problem solved
Functional benefit
Brands
- Beondblack: Private retreats offering
- Beondthebeach
- Beondresearch
Products and services
- Mood, Trauma & PTSD Treatment Program Neuroplasticity-focused clinical therapy using medically supervised ibogaine to restore adaptive neural function and emotional safety for individuals with depression, anxiety, PTSD, traumatic brain injury, and trauma, delivered at the Cancún facility within Beond's hospital-grade clinical environment.
- Chemical Dependency & Behavioral Addiction Program Neuroplasticity-focused clinical therapy using medically supervised ibogaine to interrupt maladaptive reward and stress pathways and support long-term recovery from addiction to fentanyl, opioids, stimulants, and alcohol use disorder, delivered at the Cancún facility.
- Personal Growth and Peak Performance Program Neuroplasticity-focused clinical therapy using medically supervised ibogaine to support cognitive clarity, emotional regulation, and nervous system optimization for individuals seeking personal development and peak performance.
- Beond Service (Veterans & First Responders) Specialized ibogaine-assisted treatment program designed for U.S. military veterans and first responders to recover from service-related trauma, PTSD, and addiction, with the goal of restoring purpose, resilience, and peace.
- Private Retreats (Beondblack) Private, personalized ibogaine treatment retreats offered through Beond's exclusive sub-brand for confidential, individualized treatment experiences.
Quantifiable outcome
- Over 3,000 patients treated successfully at Cancún facility
- +1 more outcomes
Companies that use Beond
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
Beond technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Beond partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights6 records
Beond competitors and assessment
Company assessmentDirect peers
- Clear Sky Recovery (formerly Ibogaine by David Dardashti): Direct competitor offering medically supervised ibogaine treatment in Cancun, Mexico for addiction and mood disorders. Closely comparable to Beond in modality (ibogaine), geography (Cancun), and patient demographic.
- Pangea Biomedics: Mexico-based ibogaine treatment clinic offering protocols for addiction, depression, and trauma. Directly comparable to Beond in substance, setting, and target patient population.
- Ambio Life Sciences: Ibogaine and psychedelic-assisted treatment provider operating in Mexico. Comparable to Beond in delivery model and target indications.
- Crossroads Ibogaine Treatment Center: Mexico-based ibogaine treatment center focused on opioid and substance use recovery. Overlaps with Beond's chemical dependency program.
- Field Trip Health: Operated a network of ketamine-assisted psychotherapy clinics in North America and Europe, competing in psychedelic-assisted mental health treatment. Comparable in delivery model, indications, and patient demographic to Beond's programs.
Broad incumbents
- Compass Pathways: Public clinical-stage psychedelic medicine company developing psilocybin therapy for treatment-resistant depression. Comparable to Beond as a regulated, evidence-driven psychedelic therapeutics player targeting overlapping indications.
- MindMed: Public psychedelic medicine company running clinical trials across LSD and ibogaine-adjacent programs for anxiety, ADHD, and substance use disorders. Comparable as a regulated psychedelic therapeutics competitor.
- ATAI Life Sciences: Public holding company backing multiple psychedelic drug developers, including ibogaine programs. Comparable to Beond as a well-capitalized psychedelic therapeutics investor/operator pursuing similar indications.
- Lykos Therapeutics (formerly MAPS Public Benefit Corp.): Developer of MDMA-assisted therapy for PTSD and related behavioral health conditions. Comparable as a regulated psychedelic therapeutics company addressing overlapping trauma and addiction indications.
Emerging players
- Mindbloom: US-based at-home ketamine-assisted therapy provider for depression, anxiety, and PTSD. Comparable to Beond as a direct-to-consumer psychedelic-adjacent mental health service targeting overlapping indications, but delivered remotely rather than through residential ibogaine treatment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Beond social profiles
Digital presenceBeond financial estimates
Financial estimateRevenue estimate
Valuation estimate
Beond leadership team
Management profileNumber of profiles
Profiles2 records
Beond funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Beond M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Beond
What does Beond do?
Beond provides medically supervised ibogaine-assisted treatment delivered in a hospital-grade clinical environment in Cancún, Mexico, treating depression, anxiety, PTSD, traumatic brain injury, trauma, and substance addictions (opioids, fentanyl, stimulants, alcohol). Treatment is structured around a proprietary 5-phase neurorestorative program that spans remote preparation, on-site medical assessment, ibogaine administration with advanced cardiac monitoring, acute integration, and long-term aftercare coaching.
Is Beond a public or private company?
Beond is a private company. It is classified as venture growth investor backed and is currently operating.
When was Beond founded?
Beond was founded in 2021. It employs 11 to 50 people.
Where is Beond based?
Beond is headquartered in San Francisco, Mexico, in the Latin America region.
How does Beond make money?
One revenue line is on record: ibogaine Treatment Services.
Who are Beond's main competitors?
Direct peers on record are Clear Sky Recovery (formerly Ibogaine by David Dardashti), Pangea Biomedics, Ambio Life Sciences, Crossroads Ibogaine Treatment Center and Field Trip Health. Broad incumbents are Compass Pathways, MindMed, ATAI Life Sciences and Lykos Therapeutics (formerly MAPS Public Benefit Corp.). Mindbloom is listed as an emerging player.
Does Beond have an API?
No public API is recorded for Beond.
What industry is Beond in?
Beond's product category is Psychedelic-Assisted Therapy. Its primary akta.pro industry code is HLAFACAE, Residential Substance Use Rehabilitation (Inpatient Rehab), with a secondary code of HLAFACAF, Outpatient Substance Use Treatment Programs (IOP/PHP/OP). Its NAICS code is 623220 and its SIC code is 8050.